By consolidating legacy buildings, Colorcon enhances environmental and production efficiencies at West Point, PA facility.
Excipient manufacturer Colorcon, Inc., has completed a multimillion-dollar expansion and renovation at its North America production facility in West Point, PA, to enhance the company’s supply chain robustness for products manufactured and delivered to oral solid dose manufacturers in North America, Central America, and Latin America.
The investment included the consolidation of multiple legacy buildings into a unified manufacturing campus, eliminating off-site warehousing, which will reduce and traffic and noise in the area, the company reported in a Dec. 18, 2019 press statement.
“The investment in our West Point, USA facility brings together expanded material warehousing and new best-in-class quality control laboratories to the existing production capabilities,” said Simon Tasker, president Americas region in the press statement. “This supports our future growth expectations, improves our environmental foot print and reduces supply lead times for our customers.”
“Colorcon’s West Point, Pennsylvania, site is one of seven film coating manufacturing sites strategically located around the world and is an important component in Colorcon’s Business Continuity Plan,” added Martti Hedman, Colorcon CEO in the press statement. “This multi-year investment helps Colorcon to further improve its service to the customers and is a good example of how Colorcon invests in new capacity ahead of demand.”
Source: Colorcon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.